2PATIX is a regenerative emergency medicine company in Houston, TX, developing a targeted biologics platform for myocardial infarction and stroke.
Our drugs target the conserved biology of ischemia reperfusion injury (IRI)—endothelial damage, inflammation, barrier failure, and cell death—with a pleiotropic, regenerative signal that is naturally activated in acute coronary syndrome or stroke.
The central idea
Infarct size is the major determinant of outcome in myocardial infarction and stroke. Hepatocyte growth factor (HGF) reduces infarct size. Our drugs are better versions of HGF.
